Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $1.38 in the prior trading day, Pacific Biosciences of California Inc (NASDAQ: PACB) closed at $1.47, up 6.52%. In other words, the price has increased by $6.52 from its previous closing price. On the day, 7.96 million shares were traded. PACB stock price reached its highest trading level at $1.5395 during the session, while it also had its lowest trading level at $1.36.
Ratios:
Our goal is to gain a better understanding of PACB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.81. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.32.
On April 18, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $7 to $2.50.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $11.Stephens initiated its Overweight rating on December 14, 2023, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’24 when Meline David W bought 40,000 shares for $4.40 per share. The transaction valued at 176,160 led to the insider holds 40,000 shares of the business.
HENRY CHRISTIAN O sold 14,177 shares of PACB for $69,056 on Mar 04 ’24. The insider now owns 2,596,670 shares after completing the transaction at $4.87 per share. On Mar 04 ’24, another insider, Van Oene Mark, who serves as the insider of the company, sold 9,186 shares for $4.87 each. As a result, the insider received 44,745 and left with 1,668,826 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 393889440 and an Enterprise Value of 693403264. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.00 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at 3.458 whereas that against EBITDA is -2.414.
Stock Price History:
The Beta on a monthly basis for PACB is 2.00, which has changed by -0.8700265 over the last 52 weeks, in comparison to a change of 0.22363698 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $14.55, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -61.55%, while the 200-Day Moving Average is calculated to be -81.20%.
Shares Statistics:
The stock has traded on average 9.79M shares per day over the past 3-months and 19305700 shares per day over the last 10 days, according to various share statistics. A total of 267.74M shares are outstanding, with a floating share count of 255.73M. Insiders hold about 6.08% of the company’s shares, while institutions hold 102.32% stake in the company. Shares short for PACB as of 1713139200 were 48520230 with a Short Ratio of 4.96, compared to 1710460800 on 45573139. Therefore, it implies a Short% of Shares Outstanding of 48520230 and a Short% of Float of 20.07.
Earnings Estimates
The current rating of Pacific Biosciences of California Inc (PACB) reflects the combined expertise of 13.0 analysts actively engaged in assessing its market performance.On average, analysts expect EPS of -$0.27 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.32, while EPS last year was -$0.36. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.22 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.89 and -$1.11 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$0.82, with 14.0 analysts recommending between -$0.52 and -$0.99.
Revenue Estimates
11 analysts predict $42.96M in revenue for the current quarter. It ranges from a high estimate of $51.4M to a low estimate of $38.75M. As of the current estimate, Pacific Biosciences of California Inc’s year-ago sales were $34.38MFor the next quarter, 11 analysts are estimating revenue of $46.63M. There is a high estimate of $58.2M for the next quarter, whereas the lowest estimate is $41.24M.
A total of 14 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $240.4M, while the lowest revenue estimate was $171.8M, resulting in an average revenue estimate of $204.67M. In the same quarter a year ago, actual revenue was $200.52MBased on 14 analysts’ estimates, the company’s revenue will be $288.16M in the next fiscal year. The high estimate is $386.5M and the low estimate is $224.97M.
